number of access : ?
number of downloads : ?
ID 114396
Author
Morimoto, Kana Tokushima University
Keywords
GH-secreting macroadenoma
somatostatin analogue
remarkable shrinkage
Content Type
Journal Article
Description
Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.
Journal Title
Internal Medicine
ISSN
13497235
Publisher
The Japanese Society of Internal Medicine
Volume
56
Issue
18
Start Page
2455
End Page
2461
Published Date
2017-09-15
Rights
The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
University Hospital
Medical Sciences
Institute of Advanced Medical Sciences